Elutia (NASDAQ:ELUT) Posts Earnings Results, Beats Expectations By $1.62 EPS

Elutia (NASDAQ:ELUT) announced its quarterly earnings results on Wednesday. The company reported $1.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $1.62, FiscalAI reports. The business had revenue of $3.30 million for the quarter, compared to analysts’ expectations of $3.30 million.

Here are the key takeaways from Elutia’s conference call:

• Elutia submitted NXT-41 to the FDA and expects clearance in the second half of 2026, with the drug‑eluting NXT-41X targeted for clearance toward the end of H1 2027 and a planned commercial launch in H2 2027.
• NXT-41X combines the NXT-41 biologic matrix with rifampin and minocycline to deliver uniform, local antibiotic coverage for roughly 30 days, a design intended to materially reduce postoperative breast‑reconstruction infections (management cited potential ≥~50% reductions versus current ad‑hoc local approaches).
• Management strengthened the balance sheet by selling BioEnvelope to Boston Scientific for $88 million, paying off senior debt, and ending Q4 with $44.4 million in cash plus escrow, which they say funds development through approval and commercialization.
• The company is exploring strategic options for SimpliDerm — a standalone acellular dermal product with reimbursement covering ~100 million lives — which could unlock value but would also remove an operating asset used today.
• Elutia says its Gaithersburg manufacturing facility can support ~$120 million in revenue on one shift, and the company has added commercial leadership and active KOL/VAC engagement to prepare for commercialization.

Elutia Stock Performance

NASDAQ:ELUT remained flat at $1.09 during trading hours on Wednesday. 183,194 shares of the company’s stock were exchanged, compared to its average volume of 270,727. The company’s 50 day simple moving average is $0.96 and its 200 day simple moving average is $0.98. The stock has a market cap of $46.54 million, a price-to-earnings ratio of -1.18 and a beta of 0.65. Elutia has a fifty-two week low of $0.50 and a fifty-two week high of $3.46.

Insider Activity at Elutia

In other Elutia news, Director Kevin Rakin bought 70,000 shares of Elutia stock in a transaction on Friday, January 30th. The stock was acquired at an average cost of $1.06 per share, with a total value of $74,200.00. Following the completion of the acquisition, the director owned 196,120 shares in the company, valued at approximately $207,887.20. This represents a 55.50% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Matthew Ferguson purchased 60,000 shares of the firm’s stock in a transaction on Wednesday, December 17th. The stock was acquired at an average price of $0.53 per share, for a total transaction of $31,800.00. Following the completion of the transaction, the chief financial officer directly owned 447,110 shares of the company’s stock, valued at approximately $236,968.30. This trade represents a 15.50% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 255,500 shares of company stock worth $189,605 in the last quarter. Company insiders own 27.60% of the company’s stock.

Hedge Funds Weigh In On Elutia

Several large investors have recently made changes to their positions in ELUT. XTX Topco Ltd purchased a new position in shares of Elutia in the second quarter worth $28,000. Jane Street Group LLC purchased a new stake in Elutia in the 1st quarter worth $48,000. Virtu Financial LLC bought a new position in shares of Elutia during the 3rd quarter valued at about $26,000. Renaissance Technologies LLC grew its position in shares of Elutia by 64.7% during the fourth quarter. Renaissance Technologies LLC now owns 102,116 shares of the company’s stock valued at $71,000 after purchasing an additional 40,123 shares in the last quarter. Finally, Citadel Advisors LLC bought a new stake in shares of Elutia in the third quarter worth about $50,000. 74.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Elutia Company Profile

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small‐molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.